References
- Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS (2016). Coexisting JAK2V617F and CALR exon 9 mutations in myeloproliferative neoplasms - Do they designate a new subtype? Asian Pac J Cancer Prev, 17, 923-6. https://doi.org/10.7314/APJCP.2016.17.3.923
- Arber DA, Orazi A, Hasserjian R, et al (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-405. https://doi.org/10.1182/blood-2016-03-643544
- Baxter EJ, Scott LM, Campbell PJ, et al (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-61. https://doi.org/10.1016/S0140-6736(05)74230-6
- Choi CW, Bang SM, Jang S, et al (2015). Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med, 30, 771-88. https://doi.org/10.3904/kjim.2015.30.6.771
- Duletic AN, Dekanic A, Hadzisejdic I, et al (2012). JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Coll Antropol, 36, 859-65
- Grinsztejn E, Percy MJ, McClenaghan D, et al (2016). The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms. Int J Lab Hematol, 38, 102-6. https://doi.org/10.1111/ijlh.12447
- Ha JS, Kim YK, Jung SI, et al (2012). Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med, 32, 385-91. https://doi.org/10.3343/alm.2012.32.6.385
- Huijsmans CJ, Poodt J, Savelkoul PH, et al (2011). Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. J Mol Diagn, 13, 558-64. https://doi.org/10.1016/j.jmoldx.2011.04.002
- Jekarl DW, Han SB, Kim M, et al (2010). JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. Korean J Hematol, 45, 46-50. https://doi.org/10.5045/kjh.2010.45.1.46
- Jelinek J, Oki Y, Gharibyan V, et al (2005). JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood, 106, 3370-3. https://doi.org/10.1182/blood-2005-05-1800
- Jones AV, Kreil S, Zoi K, et al (2005). Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, 2162-8. https://doi.org/10.1182/blood-2005-03-1320
- Kim JT, Cho YG, Choi SI, et al (2010). JAK2 V617F and exon 12 geneticvariations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms. Korean J Lab Med, 30, 567-74. https://doi.org/10.3343/kjlm.2010.30.6.567
- Kim BH, Cho YU, Bae MH, et al (2015a). JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. J Korean Med Sci, 30, 882-8. https://doi.org/10.3346/jkms.2015.30.7.882
- Kim SY, Im K, Park SN, et al (2015b). CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol, 143, 635-44. https://doi.org/10.1309/AJCPUAAC16LIWZMM
- Klampfl T, Gisslinger H, Harutyunyan AS, et al (2013). Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med, 369, 2379-90. https://doi.org/10.1056/NEJMoa1311347
- Lakey MA, Pardonani A, Hoyer JD, et al (2010). Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. Am J Clin Pathol, 133, 942-8. https://doi.org/10.1309/AJCP3Z2AKUWRGTNM
- Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC (2007). The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur J Haematol, 79, 508-15. https://doi.org/10.1111/j.1600-0609.2007.00960.x
- Levine RL, Wadleigh M, Cools J, et al (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-97. https://doi.org/10.1016/j.ccr.2005.03.023
- Lin Y, Liu E, Sun Q, et al (2015). The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol, 144, 165-71. https://doi.org/10.1309/AJCPALP51XDIXDDV
- Nangalia J, Massie CE, Baxter EJ, et al (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med, 369, 2391-405. https://doi.org/10.1056/NEJMoa1312542
- Pardanani AD, Levine RL, Lasho T, et al (2006). MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-6. https://doi.org/10.1182/blood-2006-04-018879
- Rampal R, Al-Shahrour F, Abdel-Wahab O, et al (2014). Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood, 123, 123-33. https://doi.org/10.1182/blood-2014-02-554634
- Ruan GR, Jiang B, Li LD, et al (2010). MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes. Hematol Oncol, 28, 33-9.
- Rumi E, Harutyunyan AS, Pietra D, et al (2014). CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood, 123, 2416-9. https://doi.org/10.1182/blood-2014-01-550434
- Sultan S, Irfan SM (2015a). Acquired JAK-2 V617F mutational analysis in Pakistani patients with essential thrombocythemia. Asian Pac J Cancer Prev, 16, 7327-30. https://doi.org/10.7314/APJCP.2015.16.16.7327
- Sultan S, Irfan SM (2015b). JAK-2 V617F mutational analysis in primary idiopathic myelofibrosis: experience from Southern Pakistan. Asian Pac J Cancer Prev, 16, 7889-92. https://doi.org/10.7314/APJCP.2015.16.17.7889
- Sultan S, Irfan SM, Khan SR (2016). Somatic JAK-2 V617F mutational analysis in polycythemia rubra vera: a tertiary care center experience. Asian Pac J Cancer Prev, 17, 1053-5. https://doi.org/10.7314/APJCP.2016.17.3.1053
- Scott LM, Tong W, Levine RL, et al (2007). JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med, 356, 459-68. https://doi.org/10.1056/NEJMoa065202
- Tefferi A, Wassie EA, Lasho TL, et al (2014a). Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia, 28, 2300-3. https://doi.org/10.1038/leu.2014.148
- Tefferi A, Lasho TL, Finke CM, et al (2014b). CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 28, 1472-7. https://doi.org/10.1038/leu.2014.3
- Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011). New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 118, 1723-35. https://doi.org/10.1182/blood-2011-02-292102
- Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-51. https://doi.org/10.1182/blood-2009-03-209262